Amyloidosis Registry

Condition/Intervention

  • Amyloidosis


Study Name

A Multi-Center, International Registry of Cardiac Transplantation for Light Chain (AL) and Transthyreitin (TTR) Amyloidosis


Summary

The purpose of this study is to collect data (medical information) on patients with light chain (AL) and transthyreitin (TTR) amyloidosis to assess health outcomes. In so doing, researchers aim to increase their understanding of disease presentation, progression, and various treatment plans for AL and TTR cardiac amyloidosis.

Amyloidosis is a multisystem disorder in which normally soluble protein is deposited in tissues, leading to organ dysfunction. Two of the most challenging types of amyloidosis include AL amyloidosis and TTR amyloidosis; both lead to protein deposition in vital organs, including the heart.


Inclusion Criteria

  • Adult males and females listed for heart transplant at collaborating institutions
  • Diagnosed with AL or TTR amyloidosis


Exclusion Criteria

  • Pregnancy
  • Children


Principal Investigator

Jon Kobashigawa, MD


Co-Investigator

Jignesh Patel, MD, PhD


Study Coordinator and Contact

Brandy Starks
Phone: 310-248-7141
Email: brandy.starks@cshs.org


Status

Active


IRB No.

32718


Date Last Updated

07/15